[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Portuguese Association of Interventional Cardiology\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":100},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,48,76],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":21,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":26,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100619365","perfect---portuguese-evolut-registry-studying-the-outcomes-of-medtronic-evolut-fx-tavi-system-by-evaluating-an-optimal-care-pathway-for-tavi-100619365",false,"NCT07343674","PERFECT - Portuguese Evolut Registry Studying the Outcomes of Medtronic Evolut™ FX+ TAVI System by Evaluating an Optimal Care Pathway for TAVI","PERFECT","Inclusion Criteria:\n\n* Subjects more than 18 years old, able to provide an Informed Consent:\n* Severe symptomatic (defined as New York Heart Association (NYHA) class ≥ II) aortic stenosis (AS), including but not limited to: Dyspnea at rest or on exertion, fatigue, angina, syncope in the absence of another identifiable cause;\n* Subjects provided written Informed Consent as approved by the Ethics Committee (EC);\n\nExclusion Criteria:\n\n* Subjects with pre-existing surgical bioprosthetic aortic valve;\n* Hepatic insufficiency (Child-Pugh Class B or C);\n* Contraindicated for treatment with the Medtronic Evolut™ FX+ TAVU System in accordance with the Instructions for Use (IFU);\n* Anatomically considered not suitable for the Medtronic Evolut™ FX+ TAVI system;\n* Subjects are currently participating in another clinical investigation that may confound the results of this Registry;\n* Subjects have an expected survival less than one year.","ALL","18 Years",{"count":19,"type":20},500,"ESTIMATED","1 Year","OBSERVATIONAL","The goal of this registry is to learn how the Medtronic Evolut™ FX+ transcatheter aortic valve implantation (TAVI) System performs in adults with severe, symptomatic aortic stenosis who need valve replacement.\n\nThe main questions it aims to answer are:\n\n* Can using a standardized procedure for the impantation of the Medtronic Evolut™ FX+ TAVI System increase safety and efficiency?\n* What are the short-term (30 days) and long-term (1 year) patient outcomes, including the need for a pacemaker, complications, and valve function?\n\nParticipants will undergo TAVI with the Medtronic Evolut™ FX+ TAVI System as part of their routine care.\n\nBe followed during their hospital stay, at 30 days, and at 1 year to check heart health, valve function, and recovery. 500 people at 12 hospitals in Portugal will take part in this registry.",[25],"Severe Symptomatic Aortic Stenosis (Defined as New York Heart Association (NYHA) Class ≥ II)",[27,28,29,30,31,32,33,34],"TAVI","Transcatheter Aortic Valve Implantation","Evolut FX+","Aortic Stenosis","Cusp Overlap Technique","Conduction Disorders","Evolut FX+ TAVI System","TAVI System","RECRUITING","2026-07-01",{"date":38,"type":39},"2026-07-02","ACTUAL",{"date":41,"type":39},"2026-01-14",{"date":43,"type":20},"2028-04",{"name":45,"class":46},"Portuguese Association of Interventional Cardiology","OTHER",12,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":52,"acronym":53,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":55,"targetDuration":57,"studyType":22,"phases":4,"briefSummary":58,"conditions":59,"keywords":62,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":4},"100629648","drug-coated-balloon-multicentric-registry-in-spain-and-portugal-100629648","NCT07477405","Drug-coatEd Balloon Multicentric Registry in Spain and PORTugal","DESPORT","Inclusion Criteria:\n\n1. Patient over the age of 18 years, undergoing PCI with at least one DCB attempted.\n2. Patient has provided written informed consent as approved by the Ethics Committee (EC)\n3. Patient is willing to undergo all registry procedures and follow-up requirements\n\nExclusion Criteria:\n\n1. Patients with known allergy to antiplatelet drugs or DCB antiproliferative agents\n2. Life expectancy less than 12 months\n3. Cardiogenic shock\n4. Left ventricular ejection fraction \\\u003C 15%.\n5. Any condition, which in the investigator opinion, would preclude safe participation of the patient in the registry.",{"count":56,"type":20},1200,"2 Years","Drug-eluting stents (DES) have been the main treatment option for coronary angioplasty (PCI) for many years. The antiproliferative drug in DES has the effect of preventing in-stent restenosis, which is typically a consequence of intimal hyperplasia, a characteristic phenomenon of bare metal stents (BMS).\n\nDES have shown to be safe and effective in many clinical and anatomical scenarios. There are, however, several caveats to DES, like restenosis, thrombosis, accelerated atherosclerosis, impossibility of surgical revascularization and disruption of vessel dynamics.\n\nThese phenomena have a very meaningful negative impact on patient outcomes. Drug-coated balloons (DCB) may avoid those limitations of DES and are an appealing alternative in many different scenarios. They have been the mainstay treatment of in-stent restenosis (ISR) and were formally recommended for this setting in internationally, although recent guidelines recommend DES over a DCB for a first DES restenosis. There is, however, solid evidence for their use in the context of any ISR (BMS or DES-related) and both comparing with POBA or DES. The presence of metal from previous stents makes the implantation of more stents even more of a thing to avoid.\n\nHigh bleeding risk may also be an advantageous setting for DCB, as it may allow for a shorter or less intensive anti-thrombotic treatment with the same or even improved safety endpoints when compared to BMS or DES with standard therapy.\n\nOther than ISR, there are other particularly appealing anatomical settings for DCBs such as bifurcations, small vessels and diffuse disease. In the setting of a bifurcation where only the side branch is to be treated, there is evidence that DCB is a good option and provides significantly less late luminal loss when compared to POBA. In case a stent is used in the main branch, a DCB is also a good option for the side branch.\n\nIn small vessels (\\\u003C3,0mm), in which the stent metal would be more conspicuous relative to the smaller lumen, there is strong evidence pointing to a benefit of DCB when compared to balloon angioplasty (POBA) and results at least as good as full-DES. A similar MACE rate between DCB and DES has been reported, with a benefit for DCB in terms of bleeding. In fact, also in larger vessels, DCB may lead to similarly good outcomes. DCB (alone or in combination with DES) is a good alternative to DES-only in diffuse disease.\n\nProvided that a good lesion preparation is achieved and there is no structural compromise to the vessel, the lack of a metal stent will be of benefit for any type of lesion. It will contribute to late lumen enlargement (LLE), which can happen in 40-56% of lesions treated with DCB7 and is associated with layered plaques by OCT and medial dissection after lesion preparation.\n\nEvidence for DCBs is increasing in different anatomical and clinical contexts, and there are some dedicated recommendations and consensus regarding their use. There is some data regarding real-world clinical performance of DCBs, but there is still the need for large real-world studies with different DCBs, techniques, clinical settings and anatomical contexts with long term follow-up, which is the main driver for this registry.",[60,61],"Coronary Artery Disease (CAD)","ST-elevation Myocardial Infarction (STEMI)",[63,64,65,66],"Drug-coated balloons","Percutaneous Coronary Intervention","DEB","PCI","NOT_YET_RECRUITING","2026-03-13",{"date":70,"type":39},"2026-03-17",{"date":72,"type":20},"2026-08-01",{"date":74,"type":20},"2029-12-30",{"name":45,"class":46},{"id":77,"slug":78,"hasResults":11,"nctId":79,"briefTitle":80,"officialTitle":80,"acronym":81,"eligibilityCriteria":82,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":83,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":85,"conditions":86,"keywords":89,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":98,"locationsCount":99},"100578987","portuguese-registry-with-meril-myval-thv-series---myportuval-registry-100578987","NCT06818435","Portuguese Registry With Meril Myval THV Series - MyPORTuVal Registry","MyPORTuVal","Inclusion Criteria:\n\n1. Patient over the age of 18 years with symptomatic aortic stenosis (severe AS), intended to perform TAVI procedure using Myval THV series as assessed by Heart Team.\n2. Patient has provided written informed consent as approved by the Ethics Committee (EC)\n3. Patient is willing to undergo all registry procedures and follow-up requirements\n\nExclusion Criteria:\n\n1. Patients with hyper sensitivity or allergy to aspirin, heparin, clopidogrel, ticlopidine, cobalt, nickel, chromium, molybdenum or any contrast media.\n2. Ongoing infective endocarditis or any similar infection.\n3. Pregnant or lactating females.\n4. Liver failure (Child-Pugh Class B or C)\n5. Patient is currently participating in another clinical investigation where the primary endpoint has not been achieved.\n6. Any condition, which in the investigator opinion, would preclude safe participation of the patient in the Registry.",{"count":84,"type":20},150,"A prospective, single-arm, multi-centre registry to evaluate the safety and performance of Myval THV series using Transcatheter Aortic Valve Implantation (TAVI) procedure in patients with symptomatic severe native aortic valve stenosis.",[87,88],"Aortic Valve Stenosis","TAVI(Transcatheter Aortic Valve Implantation)",[81,27,90],"Portuguese TAVI Registry","2026-01-15",{"date":93,"type":39},"2026-01-16",{"date":95,"type":39},"2025-05-13",{"date":97,"type":20},"2028-11",{"name":45,"class":46},6,""]